Results 251 to 260 of about 29,019,899 (298)

Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice. [PDF]

Pharmacogenomics J
Sharma V, McDermott JH, Keen J, Koikkalainen H, McNicoll I, Davies A, Newman WG.   +6 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

Psychometric functions for temporal discrimination: Duration or log duration? [PDF]

Behav Res Methods
García-Pérez MA, Alcalá-Quintana R.
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Benchmark of biomarker identification and prognostic modeling methods on diverse censored data. [PDF]

PLoS One
Fletcher W, Sinha S.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Vitabel: A Python Framework for Visualizing and Labelling High-Resolution Physiological Data for Critical Care Machine Learning. [PDF]

J Med Syst
Orlob S, Kern WJ, Hackl B, Wnent J, Gräsner JT, Holler M.   +5 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Reporting of Cohort and Routinely Collected Data in Randomised Controlled Trial Protocols (SPIRIT-ROUTINE): extension checklist with explanation and elaboration.

BMJ
Kearney PM, McCarthy M, Rengarajan S, O'Keeffe LM, Avery K, Chan AW, Devane D, Davies G, Gale C, Hemkens LG, Juszczak E, Kwakkenbos L, Langan SM, Lugg-Widger F, Moher D, Schmidt M, Thabane L, Thombs BD, Toader AM, Watkins A, Farrin AJ, Zwarenstein M, Sydes MR, Williamson PR, Markham S.   +24 more
europepmc   +1 more source

Agreement Between Methods Assessing Changes in Plasma Volume During Fluid Therapy-A Post Hoc Analysis of a Randomized Trial. [PDF]

Acta Anaesthesiol Scand
Grubb D, Statkevicius S, Bonnevier J, Bark B, Bentzer P.   +4 more
europepmc   +1 more source